[{"id":"6724b39f-08dd-46d5-950d-1b4b715f5e32","acronym":"","url":"https://clinicaltrials.gov/study/NCT05061017","created_at":"2021-09-29T11:53:50.927Z","updated_at":"2024-07-02T16:34:58.857Z","phase":"Phase 2","brief_title":"Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)","source_id_and_acronym":"NCT05061017","lead_sponsor":"Diwakar Davar","biomarkers":" KRAS • BRAF • ALK • MET","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • BRAF mutation • KRAS wild-type • RAS wild-type","tags":["KRAS • BRAF • ALK • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • BRAF mutation • KRAS wild-type • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • cyclophosphamide • pixatimod (PG545)"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 12/09/2021","start_date":" 12/09/2021","primary_txt":" Primary completion: 02/05/2024","primary_completion_date":" 02/05/2024","study_txt":" Completion: 03/18/2024","study_completion_date":" 03/18/2024","last_update_posted":"2024-06-04"}]